Eli Lilly struck a research collaboration with METiS TechBio to apply AI to lipid nanoparticle (LNP) design for tissue-specific drug delivery. The companies said METiS will use its AI tooling to generate LNP formulations with targeted delivery characteristics, leveraging Lilly’s late-stage development and platform depth. The agreement includes potential payments that could reach $1.1 billion contingent on milestones, underscoring how quickly the market is shifting from generic LNP know-how toward computational design aimed at improving organ targeting. For delivery-focused teams, the key implication is that LNP optimization may increasingly be driven by iterative, model-guided design cycles—potentially accelerating candidate selection and reducing downstream formulation churn.